Servier’s sevasemten came from the acquisition of the muscular dystrophy assets of Edgewise Therapeutics. While the small molecule had met the goal of a Phase 2 test in Becker muscular dystrophy, Servier said new results in a pivotal cohort do not show statistically significant benefit.
The post Servier Stumbles in Muscle Disease as Drug From $1.5B Deal Fails Pivotal Test appeared first on MedCity News.
